{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T20:31:06Z","timestamp":1774557066675,"version":"3.50.1"},"reference-count":100,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004829","name":"Science and Technology Department of Sichuan Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007620","name":"Department of Education of Liaoning Province","doi-asserted-by":"publisher","award":["QNRW2020007"],"award-info":[{"award-number":["QNRW2020007"]}],"id":[{"id":"10.13039\/501100007620","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012542","name":"Sichuan Province Science and Technology Support Program","doi-asserted-by":"publisher","award":["2023NSFSC1046"],"award-info":[{"award-number":["2023NSFSC1046"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002338","name":"Ministry of Education of the People's Republic of China","doi-asserted-by":"publisher","award":["22YJCZH065"],"award-info":[{"award-number":["22YJCZH065"]}],"id":[{"id":"10.13039\/501100002338","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.critrevonc.2023.104195","type":"journal-article","created":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T13:03:44Z","timestamp":1699103024000},"page":"104195","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Cost-effectiveness of first-line immunotherapy for advanced non-small cell lung cancer with different PD-L1 expression levels: A comprehensive overview"],"prefix":"10.1016","volume":"193","author":[{"given":"Changjin","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wentan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyu","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Xin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruomeng","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaige","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyi","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huazhang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Hui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.critrevonc.2023.104195_bib1","first-page":"74","article-title":"How to carry out a literature search for a systematic review: a practical guide","volume":"24","author":"Atkinson","year":"2018","journal-title":"Brit. J. Psych. Adv."},{"issue":"9","key":"10.1016\/j.critrevonc.2023.104195_bib2","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1080\/13696998.2020.1775620","article-title":"Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer","volume":"23","author":"Aziz","year":"2020","journal-title":"J. Med. Econ."},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104195_bib3","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s10198-021-01282-4","article-title":"A cost-effectiveness analysis of pembrolizumab with or without chemotherapy for the treatment of patients with metastatic, non-squamous non-small cell lung cancer and high PD-L1 expression in Switzerland","volume":"22","author":"Barbier","year":"2021","journal-title":"Eur. J. Health Econ.: HEPAC: Health Econ. Prev. Care"},{"issue":"6","key":"10.1016\/j.critrevonc.2023.104195_bib4","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/jama.2014.8167","article-title":"Meta-analysis as evidence: building a better pyramid","volume":"312","author":"Berlin","year":"2014","journal-title":"Jama"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104195_bib5","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1080\/13696998.2022.2077549","article-title":"Cost-effectiveness analysis of nivolumab plus ipilimumab versus platinum-doublet chemotherapy for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States","volume":"25","author":"Berling","year":"2022","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.critrevonc.2023.104195_bib6","doi-asserted-by":"crossref","first-page":"w20170","DOI":"10.4414\/smw.2019.20170","article-title":"Cost effectiveness of pembrolizumab vs chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in Switzerland","volume":"149","author":"Bhadhuri","year":"2019","journal-title":"Swiss Med. Wkly."},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104195_bib7","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1093\/annonc\/mdz060","article-title":"Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer","volume":"30","author":"Blumenthal","year":"2019","journal-title":"Ann. Oncol.: Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104195_bib8","article-title":"Evaluatin trends in private equity ownership and impacts on health outcomes, costs, and quality: systematic review","volume":"382","author":"Borsa","year":"2023","journal-title":"BMJ (Clin. Res. Ed."},{"key":"10.1016\/j.critrevonc.2023.104195_bib9","volume":"11","author":"Cai","year":"2021","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104195_bib10","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/jamaoncol.2022.7826","article-title":"Estimates and Projections of the global economic cost of 29 cancers in 204 countries and territories from 2020 to 2050","volume":"9","author":"Chen","year":"2023","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2023.104195_bib11","article-title":"Cost-utility analysis of camrelizumab plus chemotherapy versus chemotherapy alone as a first-line treatment for advanced nonsquamous non-small cell lung cancer in China","volume":"12","author":"Chen","year":"2022","journal-title":"Front. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2023.104195_bib12","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nrc3775","article-title":"Non-small-cell lung cancers: a heterogeneous set of diseases","volume":"14","author":"Chen","year":"2014","journal-title":"Nat. Rev. Cancer"},{"issue":"18","key":"10.1016\/j.critrevonc.2023.104195_bib13","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.21037\/atm-21-4294","article-title":"Atezolizumab compared to chemotherapy for first-line treatment in non-small cell lung cancer with high PD-L1 expression: a cost-effectiveness analysis from US and Chinese perspectives","volume":"9","author":"Cheng","year":"2021","journal-title":"Ann. Transl. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104195_bib14","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/00005650-200301000-00007","article-title":"Development and validation of a grading system for the quality of cost-effectiveness studies","volume":"41","author":"Chiou","year":"2003","journal-title":"Med. care"},{"key":"10.1016\/j.critrevonc.2023.104195_bib15","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.lungcan.2018.11.008","article-title":"Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France","volume":"127","author":"Chouaid","year":"2019","journal-title":"Lung Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104195_bib16","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1136\/jamia.2001.0080317","article-title":"Medical subject headings used to search the biomedical literature","volume":"8","author":"Coletti","year":"2001","journal-title":"J. Am. Med. Inform. Assoc.: JAMIA"},{"issue":"9","key":"10.1016\/j.critrevonc.2023.104195_bib17","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.annonc.2022.06.013","article-title":"Immunotherapy in unresectable stage III non-small-cell lung cancer: state of the art and novel therapeutic approaches","volume":"33","author":"Cortiula","year":"2022","journal-title":"Ann. Oncol.: Off. J. Eur. Soc. Med. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104195_bib18","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.8787","article-title":"Cost-effectiveness of nivolumab-ipilimumab combination therapy for the treatment of advanced non-small cell lung cancer","volume":"4","author":"Courtney","year":"2021","journal-title":"JAMA Netw. Open"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104195_bib19","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","article-title":"Medication compliance and persistence: terminology and definitions","volume":"11","author":"Cramer","year":"2008","journal-title":"Value Health.: J. Int. Soc. Pharm. Outcomes Res."},{"issue":"9","key":"10.1016\/j.critrevonc.2023.104195_bib20","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.11952","article-title":"Cost-effectiveness of atezolizumab combination therapy for first-line treatment of metastatic nonsquamous non-small cell lung cancer in the United States","volume":"2","author":"Criss","year":"2019","journal-title":"JAMA Netw. Open"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104195_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0228288","article-title":"Cost-effectiveness of pembrolizumab for advanced non-small cell lung cancer patients with varying comorbidity burden","volume":"15","author":"Criss","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.critrevonc.2023.104195_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102545","article-title":"Immunotherapy-based combinations in metastatic NSCLC","volume":"116","author":"Desai","year":"2023","journal-title":"Cancer Treat. Rev."},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104195_bib23","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1007\/s12325-020-01292-3","article-title":"Cost-Effectiveness Analysis Of Atezolizumab Plus Chemotherapy In The First-line Treatment Of Metastatic Non-squamous Non-small Cell Lung Cancer","volume":"37","author":"Ding","year":"2020","journal-title":"Adv. Ther."},{"issue":"9","key":"10.1016\/j.critrevonc.2023.104195_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0238536","article-title":"Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review","volume":"15","author":"Ding","year":"2020","journal-title":"PloS One"},{"key":"10.1016\/j.critrevonc.2023.104195_bib25","series-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","year":"2005"},{"issue":"15","key":"10.1016\/j.critrevonc.2023.104195_bib26","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1001\/jama.282.15.1453","article-title":"Evaluation of conflict of interest in economic analyses of new drugs used in oncology","volume":"282","author":"Friedberg","year":"1999","journal-title":"Jama"},{"key":"10.1016\/j.critrevonc.2023.104195_bib27","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.lungcan.2018.08.018","article-title":"Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small cell lung cancer","volume":"124","author":"Georgieva","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2023.104195_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.573852","article-title":"Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced non-small-cell lung cancer","volume":"12","author":"Hao","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"8","key":"10.1016\/j.critrevonc.2023.104195_bib29","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1038\/sj.bjc.6601308","article-title":"Industry-sponsored economic studies in oncology vs studies sponsored by nonprofit organisations","volume":"89","author":"Hartmann","year":"2003","journal-title":"Br. J. Cancer"},{"issue":"11","key":"10.1016\/j.critrevonc.2023.104195_bib30","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.35123","article-title":"Characteristics of cost-effectiveness studies for oncology drugs approved in the United States From 2015-2020","volume":"4","author":"Haslam","year":"2021","journal-title":"JAMA Netw. Open"},{"issue":"10066","key":"10.1016\/j.critrevonc.2023.104195_bib31","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0140-6736(16)30958-8","article-title":"Lung cancer: current therapies and new targeted treatments","volume":"389","author":"Hirsch","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2023.104195_bib32","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.3389\/fonc.2020.01649","article-title":"Cost-effectiveness analysis of nivolumab plus ipilimumab vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer","volume":"10","author":"Hu","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104195_bib33","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.lungcan.2018.07.012","article-title":"First-line pembrolizumab in PD-L1 positive non-small-cell lung cancer: a cost-effectiveness analysis from the UK health care perspective","volume":"123","author":"Hu","year":"2018","journal-title":"Lung Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2023.104195_bib34","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s40273-017-0527-z","article-title":"Cost effectiveness of pembrolizumab vs. standard-of-care chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in the United States","volume":"35","author":"Huang","year":"2017","journal-title":"PharmacoEconomics"},{"issue":"17","key":"10.1016\/j.critrevonc.2023.104195_bib35","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.2217\/imt-2019-0178","article-title":"Cost-effectiveness of pembrolizumab versus chemotherapy as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in the USA","volume":"11","author":"Huang","year":"2019","journal-title":"Immunotherapy"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104195_bib36","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1080\/13696998.2021.1937188","article-title":"Cost-effectiveness of pembrolizumab\u2009+\u2009chemotherapy versus chemotherapy and pembrolizumab monotherapy in first line treatment of NSCLC in the US - updated analyses with additional trial follow-up","volume":"24","author":"Insinga","year":"2021","journal-title":"J. Med. Econ."},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104195_bib37","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1097\/COC.0b013e3181f4799b","article-title":"Financial conflicts of interest in economic analyses in oncology","volume":"34","author":"Jang","year":"2011","journal-title":"Am. J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104195_bib38","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s10549-010-0870-7","article-title":"Conflict of interest in economic analyses of aromatase inhibitors in breast cancer: a systematic review","volume":"121","author":"Jang","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104195_bib39","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1136\/ejhpharm-2020-002208","article-title":"Cost-effectiveness analysis of pembrolizumab plus standard chemotherapy versus chemotherapy alone for first-line treatment of metastatic non-squamous non-small-cell lung cancer in China","volume":"29","author":"Jiang","year":"2022","journal-title":"Eur. J. Hosp. Pharm.: Sci. Pract."},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104195_bib40","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s40273-021-01089-4","article-title":"Modeling Challenges in Cost-Effectiveness Analysis of First-Line Immuno-Oncology Therapies in Non-small Cell Lung Cancer: A Systematic Literature Review","volume":"40","author":"Kongnakorn","year":"2022","journal-title":"PharmacoEconomics"},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104195_bib41","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jval.2021.08.009","article-title":"Cost-effectiveness of cemiplimab versus standard of care in the United States for first-line treatment of advanced non-small cell lung cancer with programmed death-ligand 1 expression \u226550","volume":"25","author":"Kuznik","year":"2022","journal-title":"Value Health.: J. Int. Soc. Pharm. Outcomes Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104195_bib42","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12943-023-01740-y","article-title":"Lung cancer immunotherapy: progress, pitfalls, and promises","volume":"22","author":"Lahiri","year":"2023","journal-title":"Mol. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104195_bib43","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1001\/jamaoncol.2015.3928","article-title":"Associations between industry sponsorship and results of cost-effectiveness analyses of drugs used in breast cancer treatment","volume":"2","author":"Lane","year":"2016","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2023.104195_bib44","series-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated Feb 2022)","article-title":"Chapter 4. Searching for and selecting studies","author":"Lefebvre","year":"2022"},{"issue":"14","key":"10.1016\/j.critrevonc.2023.104195_bib45","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.2217\/imt-2020-0112","article-title":"Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced NSCLC","volume":"12","author":"Li","year":"2020","journal-title":"Immunotherapy"},{"key":"10.1016\/j.critrevonc.2023.104195_bib46","doi-asserted-by":"crossref","first-page":"4503","DOI":"10.2147\/CMAR.S248020","article-title":"Economic evaluations of immune checkpoint inhibitors for patients with non-small cell lung cancer: a systematic review","volume":"12","author":"Li","year":"2020","journal-title":"Cancer Manag. Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104195_bib47","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1080\/13696998.2019.1570221","article-title":"Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China","volume":"22","author":"Liao","year":"2019","journal-title":"J. Med. Econ."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104195_bib48","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s11096-020-01076-3","article-title":"Cost-effectiveness of atezolizumab plus chemotherapy for advanced non-small-cell lung cancer","volume":"42","author":"Lin","year":"2020","journal-title":"Int. J. Clin. Pharm."},{"key":"10.1016\/j.critrevonc.2023.104195_bib49","article-title":"The predictive value of PD-L1 expression level in evaluating the cost-effectiveness of atezolizumab\/pembrolizumab","volume":"12","author":"Lin","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104195_bib50","article-title":"Cost-effectiveness analysis of atezolizumab versus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer with different PD-L1 expression status","volume":"11","author":"Liu","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104195_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.788569","article-title":"First-Line ICI monotherapies for advanced non-small-cell lung cancer patients with PD-L1 of at least 50%: a cost-effectiveness analysis","volume":"12","author":"Liu","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.critrevonc.2023.104195_bib52","article-title":"Cost-effectiveness of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy in metastatic non-squamous and squamous NSCLC patients With PD-L1 expression \u2265 50","volume":"12","author":"Liu","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"15","key":"10.1016\/j.critrevonc.2023.104195_bib53","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1002\/cncr.29397","article-title":"Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer","volume":"121","author":"Lo","year":"2015","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104195_bib54","first-page":"235","article-title":"Cost effectiveness of PD-L1-based test-and-treat strategy with pembrolizumab as the first-line treatment for metastatic NSCLC in Hong Kong","volume":"4","author":"Loong","year":"2020","journal-title":"Pharm. - Open"},{"key":"10.1016\/j.critrevonc.2023.104195_bib55","article-title":"The cost-effectiveness of tislelizumab plus chemotherapy for locally advanced or metastatic nonsquamous non-small cell lung cancer","volume":"13","author":"Luo","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104195_bib56","doi-asserted-by":"crossref","first-page":"118","DOI":"10.2471\/BLT.14.138206","article-title":"Thresholds for the cost-effectiveness of interventions: alternative approaches","volume":"93","author":"Marseille","year":"2015","journal-title":"Bull. World Health Organ."},{"issue":"7","key":"10.1016\/j.critrevonc.2023.104195_bib57","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s40261-022-01168-0","article-title":"Cost-effectiveness of first-line nivolumab plus ipilimumab combination therapy in advanced non-small-cell lung cancer in Japan","volume":"42","author":"Mo","year":"2022","journal-title":"Clin. Drug Investig."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104195_bib58","first-page":"53","article-title":"Examining the value and quality of health economic analyses: implications of utilizing the QHES","volume":"9","author":"Ofman","year":"2003","journal-title":"J. Manag. care Pharm.: JMCP"},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104195_bib59","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41571-022-00718-x","article-title":"At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC","volume":"20","author":"Otano","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104195_bib60","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s40258-020-00606-4","article-title":"Is the choice of cost-effectiveness threshold in cost-utility analysis endogenous to the resulting value of technology? A systematic review","volume":"19","author":"Padula","year":"2021","journal-title":"Appl. Health Econ. Health Policy"},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104195_bib61","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1007\/s12325-021-01734-6","article-title":"First-line atezolizumab for metastatic NSCLC with high PD-L1 expression: a United States-based cost-effectiveness analysis","volume":"38","author":"Peng","year":"2021","journal-title":"Adv. Ther."},{"issue":"7","key":"10.1016\/j.critrevonc.2023.104195_bib62","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1007\/s12325-021-01788-6","article-title":"Cost-effectiveness of nivolumab plus ipilimumab combined with two cycles of chemotherapy as first-line treatment in advanced non-small cell lung cancer","volume":"38","author":"Peng","year":"2021","journal-title":"Adv. Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104195_bib63","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1080\/13696998.2022.2048573","article-title":"Cost-effectiveness analysis of nivolumab plus ipilimumab plus two cycles of platinum-doublet chemotherapy versus platinum-doublet chemotherapy alone for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States","volume":"25","author":"Polyzoi","year":"2022","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.critrevonc.2023.104195_bib64","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.728440","article-title":"Cost-effectiveness of domestic PD-1 inhibitor camrelizumab combined with chemotherapy in the first-line treatment of advanced nonsquamous non-small-cell lung cancer in China","volume":"12","author":"Qiao","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104195_bib65","first-page":"365","article-title":"A review of cost-effectiveness studies of pembrolizumab regimens for the treatment of advanced non-small cell lung cancer","volume":"5","author":"Qiao","year":"2021","journal-title":"Pharm. - Open"},{"issue":"6","key":"10.1016\/j.critrevonc.2023.104195_bib66","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1200\/JCO.21.01497","article-title":"First-line immunotherapy for non-small-cell lung cancer","volume":"40","author":"Reck","year":"2022","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2023.104195_bib67","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/s41571-020-0399-6","article-title":"Immunotherapy discontinuation - how, and when? Data from melanoma as a paradigm","volume":"17","author":"Robert","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104195_bib68","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1080\/13696998.2022.2071066","article-title":"Cost-effectiveness analysis of sintilimab\u2009+\u2009chemotherapy versus camrelizumab\u2009+\u2009chemotherapy for the treatment of first-line locally advanced or metastatic nonsquamous NSCLC in China","volume":"25","author":"Rui","year":"2022","journal-title":"J. Med. Econ."},{"issue":"9","key":"10.1016\/j.critrevonc.2023.104195_bib69","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2165\/00019053-200826090-00009","article-title":"Subgroups and heterogeneity in cost-effectiveness analysis","volume":"26","author":"Sculpher","year":"2008","journal-title":"PharmacoEconomics"},{"key":"10.1016\/j.critrevonc.2023.104195_bib70","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.lungcan.2019.10.017","article-title":"Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater","volume":"138","author":"She","year":"2019","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104195_bib71","doi-asserted-by":"crossref","first-page":"355","DOI":"10.4065\/83.3.355","article-title":"Small cell lung cancer","volume":"83","author":"Sher","year":"2008","journal-title":"Mayo Clin. Proc."},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104195_bib72","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s40273-021-01108-4","article-title":"Factors Limiting Subgroup Analysis in Cost-Effectiveness Analysis and a Call for Transparency","volume":"40","author":"Shields","year":"2022","journal-title":"PharmacoEconomics"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104195_bib73","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA: a Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104195_bib74","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1186\/s12885-021-08165-0","article-title":"Treatment beyond progression with anti-PD-1\/PD-L1 based regimens in advanced solid tumors: a systematic review","volume":"21","author":"Spagnolo","year":"2021","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104195_bib75","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: a Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2023.104195_bib76","article-title":"Extended duration of treatment using reduced-frequency dosing of anti-PD-1 therapy in patients with advanced melanoma and Merkel cell carcinoma","author":"Tachiki","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"issue":"18","key":"10.1016\/j.critrevonc.2023.104195_bib77","doi-asserted-by":"crossref","first-page":"6344","DOI":"10.1002\/cam4.4191","article-title":"Determining the optimal PD-1\/PD-L1 inhibitors for the first-line treatment of non-small-cell lung cancer with high-level PD-L1 expression in China","volume":"10","author":"Teng","year":"2021","journal-title":"Cancer Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104195_bib78","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s40273-017-0606-1","article-title":"Cost-effectiveness thresholds: the past, the present and the future","volume":"36","author":"Thokala","year":"2018","journal-title":"PharmacoEconomics"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104195_bib79","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7326\/M20-1392","article-title":"a health opportunity cost threshold for cost-effectiveness analysis in the United States","volume":"174","author":"Vanness","year":"2021","journal-title":"Ann. Intern. Med."},{"issue":"10","key":"10.1016\/j.critrevonc.2023.104195_bib80","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1002\/cncr.29882","article-title":"A systematic review of the cost and cost-effectiveness studies of proton radiotherapy","volume":"122","author":"Verma","year":"2016","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104195_bib81","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s40425-018-0442-7","article-title":"A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors","volume":"6","author":"Verma","year":"2018","journal-title":"J. Immunother. Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104195_bib82","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1002\/cam4.2793","article-title":"Cost-effectiveness analysis of pembrolizumab plus chemotherapy with PD-L1 test for the first-line treatment of NSCLC","volume":"9","author":"Wan","year":"2020","journal-title":"Cancer Med."},{"issue":"20","key":"10.1016\/j.critrevonc.2023.104195_bib83","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1002\/cncr.32368","article-title":"First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non-small cell lung cancer: a United States-based cost-effectiveness analysis","volume":"125","author":"Wan","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2023.104195_bib84","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.580459","article-title":"Cost-effectiveness analysis of nivolumab plus ipilimumab for advanced non-small-cell lung cancer","volume":"12","author":"Wan","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"8","key":"10.1016\/j.critrevonc.2023.104195_bib85","doi-asserted-by":"crossref","first-page":"4354","DOI":"10.1007\/s12325-021-01828-1","article-title":"Cost-effectiveness analysis of cemiplimab versus chemotherapy as first-line treatment in advanced NSCLC with PD-L1 expression levels of at least 50","volume":"38","author":"Wang","year":"2021","journal-title":"Adv. Ther."},{"issue":"8","key":"10.1016\/j.critrevonc.2023.104195_bib86","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/s41591-021-01450-2","article-title":"Toward personalized treatment approaches for non-small-cell lung cancer","volume":"27","author":"Wang","year":"2021","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104195_bib87","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3727\/096504019X15707883083132","article-title":"Cost-utility analysis of pembrolizumab versus chemotherapy as first-line treatment for metastatic non-small cell lung cancer with different PD-L1 expression levels","volume":"28","author":"Weng","year":"2020","journal-title":"Oncol. Res."},{"key":"10.1016\/j.critrevonc.2023.104195_bib88","unstructured":"World Health Organization. Cost effectiveness and strategic planning (WHO-CHOICE). Available from: \u3008http:\/\/www.who.int\/choice\/costs\/CER_levels\/en\/\u3009."},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104195_bib89","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.21037\/tlcr-19-605","article-title":"The effect of PD-L1 categories-directed pembrolizumab plus chemotherapy for newly diagnosed metastatic non-small-cell lung cancer: a cost-effectiveness analysis","volume":"9","author":"Wu","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.critrevonc.2023.104195_bib90","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2021.743558","article-title":"Economic Evaluation of first-line camrelizumab for advanced non-small-cell lung cancer in China","volume":"9","author":"Xiang","year":"2021","journal-title":"Front. Public Health"},{"key":"10.1016\/j.critrevonc.2023.104195_bib91","article-title":"Industry sponsorship bias in cost effectiveness analysis: registry based analysis","volume":"377","author":"Xie","year":"2022","journal-title":"BMJ Clin. Res. Ed."},{"key":"10.1016\/j.critrevonc.2023.104195_bib92","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.760686","article-title":"Cost-effectiveness of nivolumab plus ipilimumab with and without chemotherapy for advanced non-small cell lung cancer","volume":"11","author":"Yang","year":"2021","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104195_bib93","first-page":"1061","article-title":"First-line atezolizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: a cost-effectiveness analysis from China","volume":"21","author":"Yang","year":"2021","journal-title":"Expert Rev. Pharm. Outcomes Res."},{"issue":"12","key":"10.1016\/j.critrevonc.2023.104195_bib94","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-031019","article-title":"Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA","volume":"9","author":"Zeng","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.critrevonc.2023.104195_bib95","article-title":"Cost-Effectiveness of Pembrolizumab for the treatment of Non-Small-Cell lung cancer: A systematic review","volume":"12","author":"Zhang","year":"2022","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104195_bib96","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/j.clon.2021.10.008","article-title":"First-line cemiplimab versus standard chemotherapy in advanced non-small cell lung cancer patients with at least 50% programmed cell death receptor ligand-1 positivity: analysis of cost-effectiveness","volume":"34","author":"Zhang","year":"2022","journal-title":"Clin. Oncol. (R. Coll. Radiol. (Gt. Br. ))"},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104195_bib97","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41423-020-00577-5","article-title":"The cutting-edge progress of immune-checkpoint blockade in lung cancer","volume":"18","author":"Zhou","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.critrevonc.2023.104195_bib98","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.lungcan.2019.08.028","article-title":"Cost-effectiveness analysis of pembrolizumab monotherapy and chemotherapy in the non-small-cell lung cancer with different PD-L1 tumor proportion scores","volume":"136","author":"Zhou","year":"2019","journal-title":"Lung Cancer (Amst., Neth. )"},{"key":"10.1016\/j.critrevonc.2023.104195_bib99","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jclinepi.2023.02.011","article-title":"Sponsorship bias in oncology cost effectiveness analysis","volume":"156","author":"Zhou","year":"2023","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.critrevonc.2023.104195_bib100","volume":"12","author":"Zhu","year":"2021","journal-title":"Front. Pharmacol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842823002834?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842823002834?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:48:43Z","timestamp":1760903323000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842823002834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":100,"alternative-id":["S1040842823002834"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2023.104195","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness of first-line immunotherapy for advanced non-small cell lung cancer with different PD-L1 expression levels: A comprehensive overview","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2023.104195","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104195"}}